Pilot study of a ketogenic diet in relapsing-remitting MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 9, 2018
- Accepted in final form March 5, 2019
- First Published April 12, 2019.
Author Disclosures
- J. Nicholas Brenton, MD,
- Brenda Banwell, MD,
- A.G. Christina Bergqvist, MD,
- Diana Lehner-Gulotta, RDN, CNSC,
- Lauren Gampper, BA,
- Emily Leytham, BA,
- Rachael Coleman, MPH and
- Myla D. Goldman, MD, MSc
- J. Nicholas Brenton, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Novartis
NONE
NONE
NONE
NONE
NONE
Translational Health Research Institute of Virginia
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brenda Banwell, MD,
Scientific Advisory Board, Biogen-IDEC, Sanofi, Eli Lilly, Novartis.
NONE
Novartis
I serve on the Editorial Board for Neurology. I receive no financial remuneration.
NONE
NONE
NONE
I have served as a consultant to Novartis.
I have spoken at an event supported by the Consortium of MS Centers, the Corpus, and Medscape
NONE
NONE
NONE
NONE
NONE
Multiple Sclerosis Society of Canada Multiple Sclerosis Scientific Research Foundation National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- A.G. Christina Bergqvist, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Diana Lehner-Gulotta, RDN, CNSC,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lauren Gampper, BA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Emily Leytham, BA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rachael Coleman, MPH and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Myla D. Goldman, MD, MSc
DSMB: Acorda Pharmaceuticals, PCORI
NONE
ADAMAS: Travel & Lodging Novartis: Travel and Lodging EMD Serono: Travel and Lodging Teva Pharmaceuticals: Travel and Lodging Genzyme: Travels and Lodging
10/2012- present: Associate Editor (Discipline Editor), SAGE Open Medical Case Reports
NONE
NONE
NONE
Consultant for ADAMAS, Celgene, ENDECE, EMD Serono, Novartis Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals.
NONE
NONE
NONE
Institutional Contracts *Biogen, Idec *Novartis Pharm. *National MS Society *PCORI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Division of Pediatric Neurology (J.N.B., D.L.-G.), Department of Neurology, University of Virginia, Charlottesville; Department of Pediatric Neurology (B.B., A.G.C.B.), University of Pennsylvania/Children's Hospital of Philadelphia; and Department of Neurology (L.G., E.L., R.C., M.D.G.), University of Virginia, Charlottesville.
- Correspondence
Dr. Brenton jnb8h{at}virginia.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.